SEC Form 4 · accession 0001562180-19-000343
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A. Velleca
Officer — President and CEO · Director
Period of report
Jan 17, 2019
Accepted (ET)
Jan 17, 2019 · 5:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 17, 2019 | M | 9,000 | $0.39 | A | 28,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $0.39 | Jan 17, 2019 | M | 9,000 | D | — | May 9, 2024 | Common Stock | 9,000 | 380,286 | D |
Explanation of responses
- F1All shares underlying this option have vested.